Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGI226 Microparticles in Achilles Tendinopathy
2022-500863-10-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Achilles tendinitis (AT) comparing NGI226 microparticles with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and serious adverse events, Local tolerability and 3 more. Started Dec 2022; status: completed.
02
Drugs
NGI226
03
Conditions
Achilles tendinitis (AT)
Beyond the preview
Go deeper on 2022-500863-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500863-10-00.